GCG and type 2 diabetes mellitus: Importantly, the effects of RAMPs are agonist and pathway dependent, with RAMP2 increasing Gαs coupling at GCGR in response to glucagon and oxyntomodulin (an endogenous dual agonist of both GCGR and GLP-1R) but decreasing the response to GLP-1 and liraglutide (a synthetic, lipidated GLP-1 mimetic, approved in the treatment of T2DM) (13).